(Q46293619)

English

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Mauricette Michallet

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Karine Goldet

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Mohamad Sobh

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Stéphane Morisset

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Youcef Chelghoum

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Xavier Thomas

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Fiorenza Barraco

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Sophie Ducastelle

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Hélène Labussière

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Catherine Renzullo

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Carole Paillet

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Christine Pivot

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Perrine Badol-Van Straaten

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Angelique Denis

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Anne Termoz

15

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Marie Detrait

16

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Franck-Emmanuel Nicolini

17

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

Isabelle Jaisson-Hot

18

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

language of work or name

0 references

publication date

28 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

119

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

107-114

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Cancer-related anemia: biological findings, clinical implications and impact on quality of life

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

The rationale for pathogen-inactivation treatment of blood components.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Transfusion-related acute lung injury: a review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

The transplant iron score as a predictor of stem cell transplant survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

21 January 2018

The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of recombinant human erythropoietin in patients of advanced cervical cancer treated "by chemoradiotherapy"

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27686

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27686

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

release_l5fnwk74wfe5nik6oluqge3wgi

1 reference

https://api.fatcat.wiki/v0/release/l5fnwk74wfe5nik6oluqge3wgi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/22744794

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46293619&oldid=2103959290"